Failure of amphotericin B spray to prevent aspergillosis in granulocytopenic patients.
We tested the efficiency of a nasal spray of Amphotericin B (AmB) in leukemic patients, in an attempt to prevent pulmonary Aspergillosis. From January to July, 8 cases of invasive Aspergillosis (IA) in 19 new leukemic patients were identified. Between July and September 15 patients were treated by prophylactic nasal spray of AmB (daily dose 5 mg). Compliance was excellent, but nevertheless typical IA developed in 5 patients. We conclude that at the dosage used prophylactic administration of nasal spray of (AmB) does not prevent IA.
Jorgensen
C J
CJ
Service d'Hématologie, Hôpital Cochin, Paris, France.
Dreyfus
F
F
Vaixeler
J
J
Guyomard
S
S
Massiot
C
C
Belanger
C
C
Brunet
F
F
Giraud
T
T
Dupuis-Camay
P
P
D000281:Administration, Intranasal; D000380:Agranulocytosis / Q000150:complications*; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D001228:Aspergillosis / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007938:Leukemia / Q000150:complications; D008172:Lung Diseases, Fungal / Q000209:etiology / Q000517:prevention & control*
D000666:Amphotericin B